BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
BioCryst (Nasdaq: BCRX) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 1:30 p.m. ET.
A live audio webcast and replay will be available in the Investors & Media section of BioCryst’s website at www.biocryst.com.
Positive
- None.
Negative
- None.
News Market Reaction – BCRX
In the Jan 6 session, BCRX gained 2.29%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | FDA approval | Positive | -0.1% | FDA approval of ORLADEYO oral pellets for pediatric HAE patients. |
| Dec 04 | Equity grants | Neutral | +0.1% | Inducement stock options and RSUs granted to new employees. |
| Dec 03 | M&A progress | Positive | +9.6% | Early termination of HSR waiting period for Astria acquisition. |
| Nov 12 | Partner earnings / M&A | Neutral | -0.7% | Astria Q3 results plus detailed BioCryst cash-and-stock deal terms. |
| Nov 06 | Clinical data update | Positive | -1.9% | APeX-P interim data showing sustained ORLADEYO attack reduction in children. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive regulatory and clinical news sometimes met with muted or negative next-day moves, while M&A milestones saw stronger positive alignment.
Over the past few months, BioCryst reported multiple milestones, including an FDA approval for ORLADEYO oral pellets for pediatric HAE on Dec 12, 2025 and progress on the Astria Therapeutics acquisition, with early HSR termination and a detailed merger prospectus. Q3 10-Q results showed profitability and ongoing ORLADEYO commercialization. Some positive clinical and regulatory updates saw limited or negative price reactions, while the Astria acquisition news on Dec 3, 2025 produced a notable 9.64% gain, underscoring stronger sensitivity to strategic M&A developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET.
A link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
